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Abstract
Background The receptor tyrosine kinase (RTK) anaplastic
lymphoma kinase (ALK) has been implicated in the tumori-
genesis of rhabdomyosarcoma (RMS). However, the exact role
of ALK in RMS is debatable and remains to be elucidated.
Objective To determine the in vitro and in vivo effects and
mechanism of action of the second-generation ALK inhibitor
ceritinib on RMS cell growth.
Methods Effects of ceritinib on cell proliferation, wound
healing, cell cycle, and RTK signaling were determined in
alveolar and embryonal rhabdomyosarcoma (ARMS,
ERMS). In addition, possible synergistic effects of combined
treatment with ceritinib and the Abl/Src family kinase inhibi-
tor dasatinib were determined.
Results Ceritinib treatment led to decreased cell proliferation,
cell cycle arrest, apoptosis, and decreased in vivo tumor
growth for the ARMS subtype. ERMS cell lines were less
affected and showed no cell cycle arrest or apoptosis. Both
subtypes lacked intrinsic ALK phosphorylation, and ceritinib
was shown to affect the IGF1R signaling pathway. High levels
of phosphorylated Src (Tyr416) were present following
ceritinib treatment, making combined treatment with a Src
inhibitor a potential treatment option. Combined treatment
of ceritinib and dasatinib showed synergistic effects in both
ERMS and ARMS cell lines.
Conclusion This study shows that monotherapy with an ALK
inhibitor, such as ceritinib, in RMS, has no effect on ALK
signaling. However, the synergistic effects of ceritinib and
dasatinib are promising, most probably due to targeting of
IGF1R and Src.
1 Introduction
Anaplastic lymphoma kinase (ALK) is a glycosylated, single-
chain trans-membrane receptor tyrosine kinase (RTK) of the
insulin receptor (InsR) superfamily. ALK was initially identi-
fied as part of an oncogenic fusion protein in anaplastic large-
cell lymphoma, and it has since been shown to be involved in
the embryonic nervous system and in tumor development [1,
2]. However, the exact role of ALK in tumor initiation and
progression remains elusive. While specific ligands are thought
to bind and activate ALK, genetic alterations and protein
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overexpression have also been shown to result in ALK activa-
tion in a ligand-independent manner. Downstream signaling
activates multiple pathways involved in cell proliferation, sur-
vival, and cell cycle progression, including PI3K/Akt, MEK/
ERK, and the JAK-STAT/Cyclin D2 pathways [3–5]. ALK
expression has been implicated in several malignancies, includ-
ing rhabdomyosarcoma (RMS), the most common pediatric
soft tissue sarcoma (STS).
RMS is a highly malignant STS seen mostly in children,
adolescents, and young adults [6]. RMS has multiple histolog-
ically distinct subtypes, of which embryonal RMS (ERMS)
and alveolar RMS (ARMS) are the most common among
pediatric patients. ERMS is typically observed in young chil-
dren and has a more favorable outcome compared to ARMS.
ERMS frequently shows a gain of chromosomes 2, 8, and 12,
loss of heterozygosity at 11p, and a higher mutational load.
ARMS has a higher metastatic rate, can present itself through-
out childhood and adolescence, and in the majority of cases a
characteristic fusion of PAX3 or PAX7 on chromosome 2 to
FOXO1 on chromosome 13 occurs, resulting in the oncogenic
fusion-protein PAX3/7-FOXO1 [7–9]. A minority of ARMS
lack the fusion, presenting with clinical and biological char-
acteristics more resembling ERMS [10]. Despite intensive
therapy, the survival of metastatic patients remains poor. In
addition, RMS survivors can suffer from immediate and late
treatment-associated toxicities, underlining the need for new,
targeted treatment strategies [7, 11, 12].
Pillay et al. were among the first to assess the expression of
ALK in RMS. ALK expression was seen in 23% of cases with
the highest expression in ARMS (45%), compared to ERMS
(15%) and other RMS subtypes (8%) [13]. ALK expression
was later associated with ALK copy number gain, metastatic
disease at diagnosis, and in some studies with a worse overall
survival (OS) [14–19]. Despite the ALK copy number gain in
ALK-positive tumors, true ALK amplification was observed in
only a small group of RMS patients [14, 19]. In addition, until
recently, no ALK rearrangements or activating mutations were
detected in RMSpatients, and even now only one case of ERMS
was shown to have an EML4-ALK fusion [18]. In line with
these findings, full-length ALK was observed in RMS tissue
samples. ALK exon deletions resulting in an immature ALK
form have been reported. However, the influence of exon dele-
tions on ALK functioning was not further examined [14, 16].
A possible explanation for the higher expression of ALK in
ARMS samples could be the high binding affinity of PAX3-
FOXO1 for the 3rd intron of ALK and its influence on ALK
transcription [20]. Some controversy on the correlation of ALK
expression with fusion status exists, and several studies could
not find a difference in specific ALK gain or ALK expression
between fusion-positive and fusion-negative RMS [19, 14, 15].
Furthermore, specific ALK copy number gain could not be cor-
related with ALK expression or RMS subtype, and it was even
suggested that the high expression levels might be the result of
the high proliferative rate of the cells [14, 15, 21]. In line with
this hypothesis, no endogenous phosphorylation of ALK has
been observed in RMS cell lines and activation of ALK could
be induced only by the addition of phosphatase inhibitors or
agonistic antibodies [16, 22, 23], making a prominent role for
ALK in RMS cell growth questionable. Silencing of ALK did
not influence RMS growth [18, 24], whereas treatment with
ALK inhibitors led to a reduction in cell proliferation and via-
bility in several RMS cell lines [25, 26]. The latter may be the
result of multi-kinase activity of the inhibitors [22, 24].
Nevertheless, independent of ALK activity, ALK might play a
role in metastatic disease, since silencing of ALK led to reduced
invasion of RMS cells in vitro, even in a non-phosphorylated
state [18].
The majority of clinical trials testing both FDA approved
and experimental ALK inhibitors focus on tumor types har-
boring ALK aberrations. Studies with specific inclusion of
ARMS or ERMS are scarce. To the best of our knowledge,
only three ongoing studies have specified the inclusion of
metastatic ARMS (NCT01548926), ERMS and ARMS pa-
tients (NCT02034981) or ALK-positive RMS patients
(NCT01742286). Preliminary data of these trials have, how-
ever, not shown any response in the included RMS patients
(Table S1), which indicates that targeting ALK in RMS does
not seem to be very promising in the clinic.
Current studies examining the preclinical effects of ALK in
RMS focused on the use of the first-generation ALK inhibi-
tors, which were associated with a moremulti-kinase targeting
profile [22, 24]. In addition, so far these agents were tested
solely in vitro. The second-generation ALK inhibitor ceritinib
has clinical activity in patients with ALK-positive, metastatic
non-small cell lung cancer (NSCLC) and was capable of over-
coming resistance to the first-generation ALK inhibitor crizo-
tinib [27, 28]. In order to further elucidate the potential of
ALK inhibition in RMS and to determine the efficacy of
second-generation ALK inhibitors in these tumors, the effects
of ceritinib were determined in ARMS and ERMS models
in vitro and on growth of ARMS models in vivo. In addition,
we studied whether combined treatment of ceritinib and
dasatinib was capable of enhancing the monotherapeutic ef-
fects of ALK inhibition in RMS.
2 Materials and Methods
2.1 Reagents
The ALK inhibitor ceritinib (LDK378) was provided by
Novartis (Basel, Switzerland). The multi-tyrosine kinase in-
hibitor dasatinib (Abl/Src family kinases) was purchased from
SelleckChem (Munich, Germany). Compounds were diluted
in DMSO or 0.5% HPMC/0.5% Tween80 for in vitro and
in vivo experiments, respectively.
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2.2 Cell Lines and Cell Culture
PAX3-FOXO1-positive ARMS (Rh30, Rh41) and -negative
ERMS (Rh18 and RD) cell lines were generously provided by
Dr. Peter Houghton. The Aska cell line was generously pro-
vided by Dr. Kazuyuki Itoh. Both ARMS cell lines were cul-
tured in RPMI 1640 medium, RD and Aska cells in DMEM
medium, and Rh18 cells in McCoy’s 5A medium (all Lonza,
Breda, The Netherlands). Media were supplemented with
10% fetal bovine serum (Gibco, ThermoFisher, Breda,
The Netherlands) and 1% Penicillin/Streptomycin (Lonza).
Cells were cultured in a humidified atmosphere of 5% CO2/
95% air at 37 °C.
2.3 Cell Viability Assay
Cell viability was assessed in MTT assays as previously de-
scribed [29]. RMS cells were seeded at 5000 cells (RD, Rh30,
and Rh41), 3000 cells (Rh18), or 10,000 cells (Aska) in
100 μl/well. Experiments were repeated in triplicate and
IC50-values were calculated with GraphPad Prism Version
5.03 software.
2.4 Wound Healing Assay and Cell Cycle Analysis
Wound healing assays and cell cycle analysis were performed
as previously described [29, 30]. For the wound healing as-
says, RMS cells were seeded at 0.6–1.5 × 106 cells/2 ml/well,
and the cell cycle analysis was performed on a BD
FACSCalibur (Franklin Lakes, NJ, USA) flow cytometer.
2.5 PathScan Analysis
The human PathScan RTK signaling antibody array kit (Cell
Signaling Technology, cat.#7949, Danvers, MA, USA) was
used according to the manufacturer’s protocol. Lysates of cells
treated with or without ceritinib (2.5 μM) for 24 h were used.
Images were analyzed with the Odyssey Infrared Imaging
System (LI-COR Biosciences, Lincoln, NE, USA) and
Odyssey Application Software (version 3.0.30). Kinase phos-
phorylation was calculated with the following equation:
Et; 1orEt; 2=xEpcð Þ*100%. Both spots on the array of a par-
ticular target (Et,1 and Et,2) were individually divided by the
average of all positive control spots on the array (x Epc) and
representative percentages were calculated. Phosphorylation is
presented as relative phosphorylation.
2.6 Western Blot
Western Blot analysis was performed as previously described
[29]. A detailed list of monoclonal antibodies used in this
study can be found in the electronic supplementary material.
The ALK-rearranged synovial sarcoma cell line Aska was
used a positive control for ALK and pALK analysis [23].
Images were analyzed with the Odyssey Infrared Imaging
System and Odyssey Application Software.
2.7 siRNA Experiments
Cells were transfected with 25 nM of a scrambled control
siRNA, or specific anti-ALK or anti-IGF1R siRNA
(Dharmacon, Lafayette, CO, USA) using Lipofectamine
2000 transfection reagents and opti-MEM medium according
to the manufacturer’s protocol (Invitrogen, Carlsbad, CA,
USA). Following transfection, the cells were either lysed for
Western Blot analysis or cell viability was determined by
MTTassay. Cell viability experiments were performed in trip-
licate and the p-value was calculated (Student’s t-test) with
GraphPad Prism Version 5.03 software. *p < 0.05,
**p < 0.01, ***p < 0.001.
2.8 In Vivo Experiments
Female Balbc/nude mice (6–8 weeks) were subcutaneously
implanted with Rh41 RMS xenografts, and experiments
were started at a tumor size of 0.1–0.6cm3 (1–2 weeks after
implantation). Ceritinib was administered daily at 25 mg/kg
or 50 mg/kg by oral gavage. Each therapy group (n = 7)
was treated for 4 weeks. Tumor growth was monitored by
caliper measurements in three dimensions (length (l), width
(w) and height (h); all maximum diameter) twice weekly.
Tumor size was calculated using the formula:4/3π x l/
2 x w/2 x h/2. Mice were euthanized on day 28. If treat-
ment was scheduled on day 28, mice were euthanized 2–
4 h post injections. Tumor sizes are depicted as relative
tumor volume (RTV = tumor volume at any time (Vt)/
tumor volume at t = 0 (Vt0)). All applicable international,
national, and institutional guidelines for the care and use of
animals have been followed. All procedures performed in
studies involving animals were in accordance with the eth-
ical standards of the animal ethical committee of the
Radboud University, Nijmegen, The Netherlands.
2.9 Immunohistochemistry (IHC)
IHC of tumor xenografts was performed to evaluate vascular-
ization (CD34), proliferation (Ki67), apoptosis (Caspase-3),
and effects on the PI3K/Akt and MEK/ERK pathways
(pAkt/pERK). A detailed description of the methodology
and analysis can be found in the supplementary material.
2.10 Combination Indices
Drug synergy of combined ceritinib and dasatinib treat-
ment was assessed by calculation of the combination
Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK... 817
index (CI) and dose reduction index (DRI). The CI and
DRI were calculated with CompuSyn software according
to the manufacturer ’s recommendation [31, 32].
Concentrations equal to 1/4xIC50 - 4xIC50-values of
ceritinib and dasatinib were combined in a constant ratio.
The monotherapy and combination therapy effects on cell
viability were determined in three independent experi-
ments and an average fraction of cell viability affected
(FA)-value was used for further calculations. Synergism
of the combination treatment is represented in an
isobologram and Table 2. The line represents an additive
effect (CI = 1) of the combination at the given FA-value.
Points below or above the line represent synergism
(CI < 1.0) and antagonism (CI > 1.0), respectively.
Points on the x-axis (ceritinib) and y-axis (dasatinib) rep-
resent the dose of the monotherapy necessary to generate
the FA-value. DRI values >1 represents a favorable dose
reduction in the combination treatment compared to the
monotherapy dose.
3 Results
3.1 Cell Viability and Cell Migration
Ceritinib affected the viability of all RMS cell lines in a dose-
dependent manner (Fig. 1, Table 1). ARMS cell lines (Rh41,
Rh30) showed a higher sensitivity compared to ERMS cell
lines (RD, Rh18), but not as high as the Aska cell line (posi-
tive control). IC50-values were 0.50 and 0.30 μM for Rh30
and Rh41, and 0.87 and 1.0 μM for RD and Rh18, respective-
ly. Ceritinib treatment did not affect the migratory ability in
any of the cell lines (data not shown).
3.2 Anaplastic Lymphoma Kinase (ALK) in ARMS
and ERMS Cell Lines
The expression of ALK and phosphorylated ALK (Tyr1507)
(pALK) was examined in the ARMS and ERMS cell lines.
ARMS cell lines expressed ALK with the highest expression
in Rh41 (Fig. 2a). ALK expressionwas observed at ~220 kDa,
representing full-length ALK, and at ~140 kDa, representing
an unglycosylated ALK protein [14]. Western Blot analysis
did not show pALK in any of the cell lines. Pathscan analysis
showed low levels of endogenous pALK in all cell lines
(Figs. 2b and c, Supplementary Fig. 2). Rh41 showed the
highest level of pALK and phosphorylation was proportional
to the level of ALK expression. All cell lines showed a corre-
lation between ceritinib sensitivity and ALK expression levels
(Table 1, Fig. 2a).
3.3 Mechanism of Action of Ceritinib in RMS Cells
The level of response (IC50 < 1 μM) and lack of intrinsic
ALK activity in the cell lines suggested an alternative target
for ceritinib in RMS cell lines. In order to investigate the
mechanism of action of ceritinib in both ARMS and ERMS
cells, we determined the dose required to affect downstream
signaling after 24 h of treatment, with a focus on the oncogen-
ic PI3K/Akt andMEK/ERK pathways. As 24 h treatment with
2.5 μM ceritinib showed a decrease in pAkt but not pERK in
all cell lines (Supplementary Fig. 3), but higher concentrations
led to excessive Rh41 cell death, we considered treatment of
2.5 μM ceritinib for 24 h the optimal dose for all subsequent
experiments concerning the evaluation of the mechanism of
action of ceritinib.
3.3.1 PathScan Analysis
In order to generate a hypothesis about the kinases involved in
ceritinib sensitivity in ARMS and ERMS, a phosphorylation
screen of 28 RTKs and 11 signaling nodes was performed
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Fig. 1 The effects of ceritinib treatment on cell viability in ARMS and
ERMS cell lines. Cells were treated with 0-5 μM ceritinib for 72 h (Rh30,
RD), 120 h (Rh41), or 144 h (Rh18, Aska) and cell viability was assessed.
The y-axis represents relative cell viability compared to non-treated cells
(control). Effects on cell viability were determined in triplicate. Values are
presented as mean ± SD. Dotted line represents the IC50-value. The
human synovial sarcoma cell line Aska with constitutive ALK phosphor-
ylation was used as a positive control
Table 1 Ceritinib and dasatinib IC50-values for ARMS and ERMS cell
lines
Treatment Cell line (IC50 ± SD)
ARMS ERMS
Rh30 Rh41 RD Rh18
Ceritinib (μM) 0.50 ± 0.19 0.30 ± 0.09 0.87 ± 0.02 1.0 ± 0.71
Dasatinib (μM) 0.64 ± 0.04 6.44 ± 0.43 6.88 ± 2.87 0.31 ± 0.18
ARMS alveolar rhabdomyosarcoma, ERMS embryonal rhabdomyosarco-
ma, IC50 concentration at which 50% of the cell viability is affected, SD
standard deviation
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Fig. 2 ALK, pALK expression, and the effect of ceritinib treatment on
RTK and signaling protein activity in ARMS and ERMS cell lines. a
Endogenous ALK and phosphorylated ALK (pALK) expression in
ARMS (Rh30, Rh41) and ERMS (RD and Rh18) cell lines as determined
byWestern Blot ((p)ALK = 220/140 kDa, Tubulin = 52 kDa). Aska cells
were used as a positive control (these cells show a deletion in ALK,
leading to constitutive activity). b Phosphorylation of 28 RTKs and 11
signaling proteins was assessed after 24 h ceritinib treatment (2.5 μM) for
bothARMS and ERMS cell lines by PathScan analysis. Untreated (−) and
treated (+) cells were compared. The boxes represent the location of
ALK, IGF1R and Src on the array. c Heatmap representing the relative
phosphorylation (as described in materials and methods) of the examined
RTKs and signaling proteins for each cell line. Boxes represent the RTKs/
signaling proteins that were further examined. d Effect of ceritinib treat-
ment on ALK activity in ARMS and ERMS cell lines (relative ALK
phophorylation) as determined by PathScan analysis
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Fig. 3 Effect of ceritinib on insulin-like growth factor-1 receptor
(IGF1R) signaling in ARMS and ERMS cell lines. a Effects of ceritinib
treatment on pIGF1R, pAkt, and pS6 by PathScan analysis. Relative
phosphorylation is shown. b Endogenous IGF1R and pIGF1R expression
in ARMS and ERMS cell lines as determined by Western Blot analysis
((p) IGF1R = 95 kDa). c Confirmation of the effects of ceritinib treatment
on pIGF1R, pAkt, and pS6 by Western Blot analysis (pAkt = 60 kDa,
pS6 = 32 kDa). Untreated cells (−) were compared to cells treated with
2.5 μM ceritinib for 24 h (+). d ALK and IGF1R expression in the Rh41,
RD, and Aska cell line in either untreated (−), scrambled siRNA (NT)
treated, or ALK/IGF1R siRNA (ALK/IGF1R) treated cells determined by
Western Blot analysis. e Relative cell viability following NT, ALK, or
IGF1R siRNA treatment in the Rh41, RD and Aska cell lines. Effects on
cell viability were determined in triplicate and untreated (control) cells
were set at 1.0. *p < 0.05, **p < 0.01, ***p < 0.001
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(n = 1) (Fig. 2b, Supplementary Figs. 1 and 2). In contrast to
the expected decrease in ALK phosphorylation, ceritinib treat-
ment led to an increase in pALK in Rh30 and RD (Fig. 2c and
d). Rh30 and Rh41 showed decreased phosphorylation of 17
and 25 RTKs upon ceritinib treatment, respectively (Fig. 2c,
Supplementary Fig. 2). The less sensitive ERMS cell lines
showed decreased phosphorylation of 1 or 6 RTKs and in-
creased phosphorylation of 18 (RD) and 4 (Rh18) RTKs upon
treatment (Fig. 2c). Both ARMS cell lines showed a decrease
in EGFR, FGFR, Her2/3, InsR, Ron, MST1R, TrkB, and
Tyro-3 phosphorylation, which could not be observed for
ERMS cell lines (Fig. 2c, Supplementary Fig. 2). In contrast,
ceritinib treatment led to an increase in phosphorylation of
multiple members of the ephrin receptor family, Tie2, and
VEGFR2 in the ERMS cell lines. Downstream signaling most
prominently decreased in Rh41 and increased in RD (Fig. 2c,
Supplementary Fig. 2).
3.3.2 IGF1R Signaling
Ceritinib treatment led to a decrease in pIGF1R and down-
stream pAkt (Ser473) in all cell lines (Figs. 2c and 3a). S6
ribosomal protein phosphorylation (pS6) was decreased in
Rh41, Rh30 and RD, and increased in Rh18 (Fig. 3a).
Western Blot analysis confirmed baseline IGF1R expression
in Rh30, Rh41 and RD, baseline pIGF1R in Rh41 and RD
(Fig. 3b) and the effects on pIGF1R, pAkt and pS6 follow-
ing treatment (Figs. 2c and 3c). IGF1R expression in Rh18,
and pIGF1R in Rh18 and Rh30 were too low to be detected
by Western Blot analysis (Fig. 3b). Knockdown of IGF1R
by siRNA led to a significant decrease in cell viability in
the Rh41 and RD cell lines. Knockdown of ALK did not
show this effect except in the pALK-positive Aska cell line
(Fig. 3d and e).
3.3.3 Cell Cycle Arrest and Apoptosis
Investigation of the possible effects of ceritinib treatment on
the cell cycle showed a G0/G1 cell cycle arrest in Rh30. Rh18
showed a decreased S-phase, but no clear cell cycle arrest.
Rh41 and RD were not affected (Fig. 4a). Rh41 and Rh30
showed apoptosis-associated PARP cleavage upon treatment,
which could not be observed in RD and Rh18 (Fig. 4b).
3.4 Effects of Ceritinib Treatment onRh41 TumorGrowth
In Vivo
In order to investigate the mechanism of action of ceritinib
in vivo, the most ceritinib-sensitive Rh41 model was selected.
Ceritinib efficacy was examined on subcutaneously implanted
Rh41 xenografts in a dose-response experiment with daily treat-
ment of 0, 25 or 50 mg/kg ceritinib for 28 days. A reduction of
tumor growth was observed after approximately 2 weeks of
treatment in both treatment groups, which continued up to
28 days of treatment (relative growth control 55.2 ± 21.9 vs.
25 mg/kg 21.2 ± 8.1, p < 0.01 or 50 mg/kg 21.3 ± 5.9, p = 0.01)
(Fig. 5). Further evaluation of tumor characteristics showed no
difference in proliferation or vascularization between the treat-
ment groups and controls or between the treatment groups, and
no differences in pERK and pAkt levels (data not shown). There
b
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Fig. 4 Cell cycle arrest and
PARP cleavage in ARMS and
ERMS cell lines upon ceritinib
treatment. a Cells were treated
with ceritinib for 24 h and stained
with propidium iodide (PI). The
level of PI was determined and
the percentage of cells in the G0-
G1, S, or G2-M phase of the cell
cycle was quantified by FACS
analysis.*p < 0.05, **p < 0.01,
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was a significant increase in caspase-3 expression in both the 25
and 50mg/kg treatment groups (Fig. 5b). Of note, when only the
outliers (n = 2/group) of the control and 50 mg/kg treatment
groups were considered (relative growth control 77.0 ± 0.3 vs.
50 mg/kg 16.6 ± 3.3, p < 0.01) (Supplementary Fig. 4), a sig-
nificant decrease in proliferation was present in the treated group
(Ki67, p = 0.021). Trends towards higher caspase-3 expression
(p = 0.0604) and more vascularization in the treated group were
observed as well in these outliers (CD34, p = 0.077).
3.5 Src Signaling and Combination Experiments
All cell lines showed high levels of pSrc (pan-Tyr) before and
after ceritinib treatment (Fig. 2c, Supplementary Fig. 2).
Ceritinib did not affect pSrc in Rh30 and Rh18. RD showed
a slight increase and Rh41 showed a decrease upon treatment
but remained the cell line with the highest level of pSrc
(Fig. 6a). Western Blot analysis of autophosphorylation-
associated pSrc (Tyr416) revealed, again, high levels of pSrc
before and after ceritinib, making the combination of ceritinib
and the Abl/Src inhibitor dasatinib of interest (Fig. 6b). IC50-
values of dasatinib showed differences in sensitivity between
the cell lines (Table 1). Rh30 and Rh18 showed IC50-values
<0.5 μM, whereas Rh41 and RD showed an IC50 of >5 μM.
Combined treatment of dasatinib and ceritinib showed a
trend towards higher cell viability inhibition when compared
to the individual monotherapies (Fig. 7a). Possible synergistic
effects were further evaluated and synergism was observed in
all cell lines (Fig. 7b), even at low dose combinations (data not
shown). The Rh30 and RD cell lines showed CI-values <1
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Fig. 5 Treatment effects on
ARMS tumor xenograft growth.
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volume of control and treated
mice. Values are presented as
mean ± SD. b Graphic
representation of relative tumor
growth for the control and treated
(25 or 50 mg/kg) groups.
Quantitative
immunohistochemical analysis of
caspase-3 levels for all three
treatment groups. Values are
presented as mean ± SD,
*p < 0.05, **p < 0.01
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Fig. 6 Effects of ceritinib treatment on Src phosphorylation in ARMS
and ERMS cell lines. a Effects of treatment on pan-tyrosine phosphory-
lation of Src (pSrc) by PathScan analysis. Relative phosphorylation is
shown. b Effects of 24 h ceritinib treatment on pSrc (Tyr416) as analyzed
by Western Blot (pSrc = 60 kDa). Untreated cells (−) were compared to
cells treated with 2.5 μM ceritinib (+). Quantification of fluorescent sig-
nal is given below, representing pSrc divided by Tubulin
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Fig. 7 Evaluation of synergism
for dasatinib and ceritinib
combination treatment in ARMS
and ERMS cell lines. a ARMS
(Rh41, Rh30) and ERMS (RD,
Rh18) cell lines were treated with
a range of dasatinib and ceritinib
concentrations (1/4× IC50 – 4×
IC50) either as mono- or
combined therapy and the fraction
of the cell viability (FA-value)
affected by the treatment was
calculated. Bars represent the
mean ± SD. X-axis represents the
fraction of the IC50-value used
for treatment. b Isobolograms
show synergistic effects of the
combination treatment at a FA-
value of 0.5, 0.75 and 0.9 for each
cell line. Points on the x-axis
(ceritinib) and y-axis (dasatinib)
represent monotherapy doses
necessary to generate the given
FA-value. Line connecting the x-
and y-axis represent an additive
effect of the combination
(CI = 1.0). Points below and
above the line represent
synergism (CI < 1.0) and
antagonism (CI > 1.0),
respectively
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(0.342–0.563) with a favorable dose reduction for both
dasatinib and ceritinib (DRI > 1) at all examined combinations
(Table 2, Fig. 7b). Rh41 showed lower levels of synergism
(0.681–0.831) and dose reduction compared to other cell
lines. However, the combination of dasatinib and ceritinib
was favorable in this cell line. Rh18 showed strong synergism
(CI < 0.3) at higher inhibitory concentrations with a strong
DRI indicating that, in particular, higher inhibitory concentra-
tions generate strong synergistic effects (Table 2, Fig. 7b).
4 Discussion
In this study, we aimed to elucidate the mechanism of action
and the potential of ALK inhibition in RMS. The underlying
reason for this is that although several clinical studies are
evaluating the effects of ALK-targeting in RMS patients, the
exact role of ALK in these tumors remains questionable. No
effects have been reported in RMS in the clinic so far, urging
the need to critically re-evaluate the potential of ALK as a
target for RMS therapy. Previous research into the role of
ALK in RMS has led to the discovery of full-length ALK in
RMS, with a predilection for the ARMS phenotype.
Accordingly, a similar preference for ARMS was observed
in our study with higher sensitivity to ALK-targeted therapy.
However, instead of the expected decrease in ALK activity
upon treatment, nearly undetectable endogenous levels of
pALK were observed. This lack of intrinsic ALK activity
was previously observed in ARMS cell lines [22, 23]. Peron
et al. further showed that the activation of ALK is dependent
on the induction of autophosphorylation by agonistic antibod-
ies and the activity of cytoplasmic phosphatases [22].
However, the cytotoxicity seen upon treatment does suggest
an alternative target of ceritinib may be present in ARMS and
ERMS cell lines.
In line with previous findings [33], ceritinib led to a de-
crease in IGF1R activity in all cell lines. Cellular signaling
activity was decreased by inhibition of the PI3K/Akt/S6 path-
way with the exception of one ERMS cell line. In this cell line
a decrease in pAkt was accompanied by an increase in S6
activity. pS6 is regulated by both the PI3K/Akt and the
MEK/ERK pathways [34, 35]. The ERMS cell lines showed
an increased ERK activity post ceritinib treatment, possibly
explaining the observed increase in pS6. The role of IGF1R in
the mechanism of action of ceritinib was further investigated
by silencing of IGF1R and ALK. IGF1R knockdown reduced
viability in the RMS cell lines, whereas knockdown of ALK
had no effect. Of note, the Aska cell line with constitutively
active ALK did show reduced viability following ALK
siRNA treatment. This further shows that the reduction in cell
viability in RMS cell lines upon ceritinib treatment is likely
dependent on decreased IGF1R activity, rather than ALK
activity.
Further examination of the mechanism of action of ceritinib
showed a clear distinction between ARMS and ERMS.
Ceritinib treatment predominantly increased RTK phosphory-
lation in ERMS compared to decreased RTK phosphorylation
in ARMS. In addition to the increased phosphorylation, the
lack of cell cycle arrest and apoptosis strengthens the idea that
upon ceritinib treatment, ERMS cells increase phosphoryla-
tion of compensatory pathways to prevent cell death. ARMS,
on the other hand, showed a clear induction of apoptosis-
associated PARP cleavage and a cell cycle arrest in one cell
line (Rh30). No cell cycle arrest was observed in Rh41. This
difference might be explained by the p53-status of the ARMS
cell lines. Rh41 harbors a p53 (c. 700_712del) mutation, while
Rh30 is p53 wild-type. p53 is the main regulator of the G1
checkpoint, and loss of p53 leads to the loss of the G0/G1
checkpoint [36]. Hypothetically, the altered oncogenic signal-
ing caused by ceritinib can lead to cellular stress and induce
the expression of p53 in Rh30, resulting in a G0/G1 cell cycle
arrest and induction of apoptosis [36, 37]. In Rh41, a G0/G1
arrest cannot be induced and the cell cycle is continued.
However, upon cellular stress the lack of p53 can lead to
premature exit of the cells from the G2 to M phase. This
premature exit of the cell might prevent proper mitosis and
lead to the induction of cell death [36, 38].
Based on the current results, it can be said that ceritinib
monotherapy has a greater effect on ARMS tumor cell growth
compared to ERMS. In vivo, ARMS xenograft growth was
inhibited by ceritinib treatment with a significant increase in
caspase-3 levels. The detected increase of caspase-3, in addi-
tion to the in vitro observed increased PARP cleavage, suggest
that the effect of ceritinib on cell viability is mediated by
caspase-dependent apoptosis [39]. Due to large variations in
tumor volume in all treatment groups, the mechanism of ac-
tion of ceritinib in vivo was difficult to examine. Interestingly,
when only the outliers of the control and 50 mg/kg treatment
Table 2 Combination index (CI) and dose reduction index (DRI) for
the combination treatment of dasatinib and ceritinib in ARMS and ERMS
cell lines
FA-value CI (DRI dasatinib, ceritinib)
0.5 0.75 0.9
ARMS Rh30 0.415 (5.91;4.07) 0.370 (10.9;3.59) 0.365 (19.9;3.18)
Rh41 0.681 (2.24;4.27) 0.710 (2.51;3.21) 0.769 (2,81;2,42)
ERMS RD 0.563 (5.48;2.62) 0.464 (5.83;3.42) 0.385 (6.21;4.46)
Rh18 0.619 (2.54;4.45) 0.187 (11.8;9.74) 0.065 (55.1;21.3)
Calculated by CompuSyn software
CI Combination index, DRI Dose reduction index, FA-value fraction of
cell viability affected by treatment, ARMS alveolar rhabdomyosarcoma,
ERMS embryonal rhabdomyosarcoma
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groups were further evaluated, a significant decrease in pro-
liferation and a trend towards higher caspase-3 levels was
observed, indicating that ceritinib treatment in vivo can reduce
tumor growth in a manner similar to that established in vitro.
However, no complete tumor loss was observed upon treat-
ment, making monotherapy with ceritinib an unlikely treat-
ment option for ARMS.
In order to determine whether combination treatment could
enhance the anti-tumor effect of ceritinib, combined treatment
with the Abl/Src inhibitor dasatinib was examined for both
ARMS and ERMS in vitro. Src is known to modulate the
activity of multiple signaling pathways by interaction with
both receptors at the cell membrane and downstream signaling
proteins [40]. Even though it was one of the first identified
tyrosine kinases, the exact role of Src in oncogenesis is still
not clear [41]. Src activity is mediated via the phosphorylation
of multiple tyrosine kinase domains with opposing functions.
Phosphorylation at Tyr527/Tyr530 leaves Src in an inactive
conformation, while dephosphorylation of this domain leads
to conformational changes and allows the autophosphorylation
at Tyr416/Tyr419 and the binding and phosphorylation of Src
substrates [41]. Since all cell lines showed high levels of pSrc
(Tyr416), even following ceritinib treatment, and Src is known
to be of importance in sarcoma and was previously shown to
increase following IGF1R treatment in RMS, the combination
of ceritinib with dasatinib was considered of interest [42, 43].
The synergistic effects and favorable dose reduction indices
suggest the combination of dasatinib and ceritinib may be fa-
vorable in both ARMS and ERMS cell lines.
The current study contributes to the hesitations
concerning ALK targeting in RMS. Despite the clear dis-
tinction between ARMS and ERMS in sensitivity to
ceritinib and the in vivo decrease in tumor growth, the lack
of intrinsic ALK activity and the lack of cell growth reduc-
tion following ALK knockdown cast doubt on the role of
ALK in RMS tumorigenesis. Moreover, ceritinib was
shown to inhibit IGF1R activity. Unfortunately, clinical
trials testing IGF1R inhibitors in RMS have shown limited
results as well, making a monotherapeutic treatment with
either ceritinib or more specific IGF1R inhibitors undesir-
able [44, 45]. However, the synergistic effect of the in vitro
combination of ceritinib and the Abl/Src kinase family in-
hibitor dasatinib does underline the potential of combined
IGF1R and Src targeted therapy in both ARMS and ERMS.
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